Characterizing diabetic cardiomyopathy: baseline results from the ARISE-HF trial
Authors' conclusion
Baseline data from the ARISE-HF Trial provide clinical characterization of individuals with T2DM and features of stage B HF, and may help clarify the diagnosis of DbCM.
Study context
- Population
- Participants of the ARISE-HF trial with T2DM and findings consistent with diabetic cardiomyopathy (Stage B heart failure (HF)); mean age 67.4 years, 50% female, mean T2DM duration 14.5 years
- Participants
- 691 participants
- Outcome
- Baseline characteristics
- Follow-up
- Baseline
Methodological detailsbaseline analysis of ARISE-HF trial participants, K-means cluster phenogroups
- Baseline analysis of ARISE-HF trial participants
- K-means cluster phenogroups
Main finding
As reported in the abstract
- NT-proBNP, median (Q1, Q3)
- 71 (35, 135) ng/L
- High-sensitivity cardiac troponin T, median [Q1, Q3]
- 9 [6, 12] ng/L
- Reduced global longitudinal strain
- 25.3%
- Impaired diastolic relaxation
- 17.7%
- Average Physical Activity Scale of the Elderly (PASE) score (markedly impaired), despite rather well-preserved Kansas City Cardiomyopathy Questionnaire (KCCQ) scores
- 155
- Average maximal oxygen consumption on cardiopulmonary exercise testing (CPET)
- 15.7 mL/Kg/minute
- K-means phenogroups identified, incl. a higher-risk group with older age, higher cardiac biomarkers, more diastolic dysfunction and LV hypertrophy
- 4
Observational data: associations, not effects.
Original publication
Characterizing diabetic cardiomyopathy: baseline results from the ARISE-HF trial. Cardiovasc Diabetol. Published 1 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →